Fecal Level of Calprotectin Identifies Histologic Inflammation in Patients With Ulcerative Colitis in Clinical and Endoscopic Remission

被引:113
作者
Guardiola, Jordi [1 ]
Lobaton, Triana [1 ]
Rodriguez-Alonso, Lorena [1 ]
Ruiz-Cerulla, Alexandra [1 ]
Arajol, Claudia [1 ]
Loayza, Carolina [2 ]
Sanjuan, Xavier [2 ]
Sanchez, Elena [1 ]
Rodriguez-Moranta, Francisco [1 ]
机构
[1] Hosp Univ Bellvitge, Dept Gastroenterol, Inst Invest Biomed Bellvitge, Barcelona 08907, Spain
[2] Hosp Univ Bellvitge, Dept Pathol, Inst Invest Biomed Bellvitge, Barcelona 08907, Spain
关键词
Mucosal Healing; Deep Remission; Histologic Remission; IBD; BOWEL-DISEASE; MUCOSAL INFLAMMATION; BLOOD LEUKOCYTES; CROHNS-DISEASE; RISK-FACTOR; RELAPSE; MARKERS; PREDICTION; NEOPLASIA; PROTEIN;
D O I
10.1016/j.cgh.2014.06.020
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BACKGROUND & AIMS: Histologic recovery of patients with ulcerative colitis (UC) often is incomplete, even among those in clinical and endoscopic remission. Persistent active microscopic inflammation is associated with an increased risk of relapse and colorectal neoplasia. A high level of fecal calprotectin (FC) is a reliable marker of endoscopic lesions in patients with UC. We evaluated the accuracy of FC in identifying patients with UC in clinical and endoscopic remission who still have histologic features of inflammation. METHODS: We performed a prospective observational study of 59 patients with UC in clinical and endoscopic remission undergoing colonoscopy. Several biopsy specimens were collected from each colonic segment. Endoscopic remission was defined as a Mayo endoscopic subscore with a grade of 0 or 1. Active histologic inflammation was defined by the presence of neutrophils infiltrating crypt epithelial cells. FC was determined by enzyme-linked immunosorbent assay analysis. RESULTS: Eighteen patients (30.5%) showed evidence of active histologic inflammation. Patients with active histologic inflammation had a significantly higher median level of FC (278 mu g/g; interquartile range, 136-696 mu g/g) than those without active histologic inflammation (68 mu g/g; interquartile range, 30-172 mu g/g) (P = .002). In multivariate analysis, the FC and Mayo endoscopic subscore (0 or 1) were each independent predictors of histologic inflammation. The level of FC identified active histologic inflammation in patients in clinical and endoscopic remission, with an area under the receiver operator characteristic curve value of 0.754. CONCLUSIONS: Histologic inflammation is common among patients with UC in clinical and endoscopic remission. Patients with histologic features of inflammation can be identified reliably based on their fecal level of calprotectin.
引用
收藏
页码:1865 / 1870
页数:6
相关论文
共 24 条
  • [1] Majority of patients with inflammatory bowel disease in clinical remission have mucosal inflammation
    Baars, Judith E.
    Nuij, Veerle J. A. A.
    Oldenburg, Bas
    Kuipers, Ernst J.
    van der Woude, Christien J.
    [J]. INFLAMMATORY BOWEL DISEASES, 2012, 18 (09) : 1634 - 1640
  • [2] BERNSTEIN CN, 1995, GASTROINTEST ENDOSC, V42, P232, DOI 10.1016/S0016-5107(95)70097-8
  • [3] Prognostic Value of Serologic and Histologic Markers on Clinical Relapse in Ulcerative Colitis Patients With Mucosal Healing
    Bessissow, Talat
    Lemmens, Bart
    Ferrante, Marc
    Bisschops, Raf
    Van Steen, Kristel
    Geboes, Karel
    Van Assche, Gert
    Vermeire, Severine
    Rutgeerts, Paul
    De Hertogh, Gert
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2012, 107 (11) : 1684 - 1692
  • [4] Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis
    Bitton, A
    Peppercorn, MA
    Antonioli, DA
    Niles, JL
    Shah, S
    Bousvaros, A
    Ransil, B
    Wild, G
    Cohen, A
    Edwardes, MDD
    Stevens, AC
    [J]. GASTROENTEROLOGY, 2001, 120 (01) : 13 - 20
  • [5] Early Mucosal Healing With Infliximab Is Associated With Improved Long-term Clinical Outcomes in Ulcerative Colitis
    Colombel, Jean Frederic
    Rutgeerts, Paul
    Reinisch, Walter
    Esser, Dirk
    Wang, Yanxin
    Lang, Yinghua
    Marano, Colleen W.
    Strauss, Richard
    Oddens, Bjoern J.
    Feagan, Brian G.
    Hanauer, Stephen B.
    Lichtenstein, Gary R.
    Present, Daniel
    Sands, Bruce E.
    Sandborn, William J.
    [J]. GASTROENTEROLOGY, 2011, 141 (04) : 1194 - 1201
  • [6] Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease
    Costa, F
    Mumolo, MG
    Ceccarelli, L
    Bellini, M
    Romano, MR
    Sterpi, C
    Ricchiuti, A
    Marchi, S
    Bottai, M
    [J]. GUT, 2005, 54 (03) : 364 - 368
  • [7] A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis
    D'Haens, Geert
    Sandborn, William J.
    Feagan, Brian G.
    Geboes, Karel
    Hanauer, Stephen B.
    Irvine, E. Jan
    Lemann, Marc
    Marteau, Philippe
    Rutgeerts, Paul
    Scholmerich, Jurgen
    Sutherland, Lloyd R.
    [J]. GASTROENTEROLOGY, 2007, 132 (02) : 763 - 786
  • [8] Results of the 2nd part Scientific Workshop of the ECCO (II): Measures and markers of prediction to achieve, detect, and monitor intestinal healing in Inflammatory Bowel Disease
    Daperno, Marco
    Castiglione, Fabiana
    de Ridder, Lissy
    Dotan, Iris
    Farkkila, Martti
    Florholmen, Jon
    Fraser, Gerald
    Fries, Walter
    Hebuterne, Xavier
    Lakatos, Peter Laszlo
    Panes, Julian
    Rimola, Jordi
    Louis, Edouard
    [J]. JOURNAL OF CROHNS & COLITIS, 2011, 5 (05) : 484 - 498
  • [9] Mucosal healing in inflammatory bowel disease: Results from a Norwegian population-based cohort
    Froslie, Kathrine Frey
    Jahnsen, Jorgen
    Moum, Bjorn A.
    Vatn, Morten H.
    [J]. GASTROENTEROLOGY, 2007, 133 (02) : 412 - 422
  • [10] A reproducible grading scale for histological assessment of inflammation in ulcerative colitis
    Geboes, K
    Riddell, R
    Öst, A
    Jensfelt, B
    Persson, T
    Löfberg, R
    [J]. GUT, 2000, 47 (03) : 404 - 409